gemcitabine + capecitabine + sorafenib

This is a combination regimen of three small molecule chemotherapeutic agents—gemcitabine, capecitabine, and sorafenib—used experimentally in the treatment of advanced cancers such as renal cell carcinoma and pancreatic adenocarcinoma. - Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA during replication, leading to apoptosis in rapidly dividing cells. - Capecitabine is an oral prodrug converted to 5-fluorouracil (5-FU) in vivo, which inhibits thymidylate synthase and disrupts DNA synthesis. - Sorafenib is an oral multikinase inhibitor targeting RAF kinases (including BRAF), vascular endothelial growth factor receptors (VEGFR), and platelet-derived growth factor receptor beta (PDGFRB), thereby inhibiting tumor cell proliferation and angiogenesis. The combination has been studied primarily for its potential synergistic antitumor effects but requires dose adjustments due to overlapping toxicities such as hand-foot syndrome[1][2][3].

Brand names

NexavarXeloda

Other names

chemo-switch regimenSOGUG regimen